Sign in
CompletedNo phase

Artificial Intelligence to Improve Detection and Risk Stratification of Acute Pulmonary Embolism (AID-PE)

Key facts

Who runs it
Royal United Hospitals Bath NHS Foundation Trust
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
3,872 people enrolled
Started
8 Jan 2024
Ended
6 Feb 2025
Type of study
Observational, 2 groups
Treatments tested
  • Artificial Intelligence
Record updated
13 February 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patients over 18 years of age
  • Patient requiring CTPA to exclude or diagnose acute PE

Who cannot take part

  • Patients under 18 years of age
  • Patients who have registered with the national opt-out scheme for research
  • CTPA performed for reasons other than acute PE
  • CTPA performed for acute PE but reported by external radiologists
  • Incomplete or discontinued CTPA scans
  • Insufficient quality CTPA to allow for analysis by a radiologist

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this exploratory observational study is to assess the feasibility and real-world clinical impact of implementing Artificial Intelligence (AI) software for the detection of acute Pulmonary Embolism (PE) in patients who undergo Computed Tomography Pulmonary Angiogram (CTPA). The main questions that this study aims to answer are:

Read full original descriptionShow less

[Question 1] What is the real-world impact of AI on the clinical outcomes and decision making by radiologists and clinicians in the management of acute PE?

[Question 2] Is AI software for the detection of acute PE acceptable to use in clinical practice and do they have a favourable impact on clinical workload?

[Question 3] Is it cost-effective to implement AI software for the detection of acute PE in clinical practice?

Patients having a CTPA for the detection of acute PE will have their imaging analysed by AI software in combination with a human radiologist. Researchers will aim to compare the clinical and radiology specific outcomes with a retrospective cohort of patients who have had standard routine radiology reporting.

The 2 groups in the trial

  • Prospective Cohort: 'Live' Introduction of AI technology

    Consecutive CTPAs, for patients with suspected acute PE, which have their imaging interpreted 'live' by AI technology. The radiologist will have ultimate responsibility for the report generated.

    Treatment: Artificial Intelligence

  • Comparator Cohort: Standard Radiology reporting

    Retrospective CTPAs, for patients with suspected acute PE, which have been reported by a human radiologist only. These CTPAs will not be interpreted by AI technology 'live' BUT undergo analysis to help assess the sensitivity, specificity, false negative, false positive rates of AI technology.

    Treatment: Artificial Intelligence

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Developing Artificial Intelligence Solutions to Improve Diagnosis and Risk Stratification in Acute Pulmonary Embolism
Publications
Record updated
13 February 2025